Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate.
Aime
S
S
Canavese
C
C
Stratta
P
P
D002614:Chelating Agents / Q000627:therapeutic use*; D000075202:Contraindications; D005355:Fibrosis; D005682:Gadolinium / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D007811:Lanthanum / Q000627:therapeutic use*; D012871:Skin Diseases / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration; D014511:Uremia / Q000188:drug therapy*
D002614:Chelating Agents; C119467:lanthanum carbonate; D007811:Lanthanum; D005682:Gadolinium